TORONTO, ON / ACCESSWIRE / February 24, 2020 / The Board of Directors of the Canadian Vehicle Manufacturers' Association / l'Association canadienne des constructeurs de véhicules (CVMA) today announced that the Association's President Mark Nantais has decided to retire effective April 1, 2020 after 36 years with the CVMA.

The CVMA Board, including the Presidents of FCA Canada, Ford of Canada and General Motors Canada extended its congratulations and sincere thanks to Mr. Nantais for his major contributions to the success of Canada's automotive industry over the past three decades.

Mark Nantais has represented Canada's leading automakers and exporters as CVMA President throughout periods of prosperity and economic and technological change, successive North American and international trade agreements and as a leading voice for the sector on numerous collaborative groups and committees.

"Mark will be greatly missed for his tremendous knowledge of the complex automotive regulatory environment in North America including trade, safety, environmental, consumer and countless other matters," said CVMA Chair and FCA Canada COO David Buckingham. "As our long-standing CVMA President, Mark has earned the respect and admiration of our members, the CVMA staff, governments and our many industry partners across Canada. We wish Mark and his family all the very best for a healthy and well-earned retirement."

– 30 –

The Canadian Vehicle Manufacturers' Association is the industry association that has represented Canada's leading manufacturers of light and heavy duty motor vehicles for more than 90 years. Its membership includes FCA Canada Inc.; Ford Motor Company of Canada, Limited and General Motors of Canada Company. Collectively its members operate 4 vehicle assembly plants as well as engine and components plants, and have over 1,300 dealerships. 136,000 jobs are directly tied to vehicle assembly in Canada. Direct and indirect jobs associated with vehicle manufacturing are estimated at over 792,000 across Canada. Please visit www.cvma.ca.

SOURCE: Canadian Vehicle Manufacturers' Association

ReleaseID: 577539

EATONTOWN, NJ / ACCESSWIRE / February 24, 2020 / Discovery Data, the leading provider of data and analytics on firms and professionals in the financial services and insurance industries, announced that it has appointed Robert Skea as the company's new Chief Executive Officer. Effective immediately, he will assume day-to-day leadership of the company and will also join Discovery Data's Board of Directors.

Bob Skea

Over a 30-year career, Skea has held a succession of executive positions leading global organizations in the financial technology and information services arenas. Prior to Discovery Data, he was most recently Managing Partner and Founder of Decklor Consulting Group, and before that Head of Americas at Dun & Bradstreet where he was responsible for all revenue and client engagement. He began his career at Chase Manhattan Bank and held C-level and senior management roles at Chase, ICE Data Services, Northstar Systems International and Reuters before Dun & Bradstreet.

Skea also serves on the Rutgers University Leadership Development Program and the New Jersey City University Athletics Department Advisory Boards and is a member of the Board of Directors for the All Stars Project of New Jersey, a Newark-based organization supporting inner-city youth with after school development programs.

"It is an honor to become the CEO of this market-leading company providing critical datasets and integrated services to help the financial services and insurance industries make informed business decisions," said Skea. "I have a deep respect for all the work that has taken place over the years at Discovery Data, and I look forward to working closely with our talented team members to deliver innovative solutions to our clients."

"We are excited to have Bob join the team for Discovery Data's next stage of growth. We feel that his combination of executive leadership, go to market strategy and deep understanding of the financial and insurance information verticals provides the perfect mix of experience to drive the company's continued expansion and success," stated John Stanfill, Chairman of Discovery Data.

About Discovery Data
Discovery Data offers a consolidated view of the financial services and insurance industries, including all BD and RIA firms, over 725,000 reps, 2,200 trust companies and over 2 million insurance agents. Access to the firm's data is provided via subscription to an online portal and through Discovery Data's CRM and API integrations. In addition, Discovery Data is the industry leader in data hygiene services and expert in data-driven market insight, email marketing campaigns and outbound call center lead generation. Many of the world's largest and most successful institutions rely on Discovery Data to understand the industry, and to identify, reach and do business with firms and professionals throughout North America. For more information, please visit www.discoveryco.com.

Press Contact:
Michelle Klotz
press@discoveryco.com
732-933-1899​​

SOURCE: Discovery Data

ReleaseID: 577332

GreenPower Announces Fiscal Third Quarter Earnings Conference Call to be Held on February 27, 2020

VANCOUVER, CANADA / ACCESSWIRE / February 24, 2020 / GreenPower Motor Company Inc. (TSXV:GPV) (OTCQB:GPVRF) ("GreenPower"), a leading designer, manufacturer, and distributer of a diverse line of electric powered buses for the transit, shuttle, tourist and school sectors, plans to host a conference call and webcast for all shareholders and interested parties at 1:30 p.m. PST / 4:30 p.m. EST on Thursday February 27, 2020 to discuss its financial results for the fiscal third quarter ended December 31, 2019. A replay of the call will be available on the number below shortly after the call.

Conference Call Information:

Date: Thursday February 27, 2020
Time: 1:30 p.m. PST / 4:30 p.m. EST

Participant dial-in: (US) 1-877-270-2148; (Canada) 1-866-605-3852; (International) 1-412-902-6510
Please ask to be joined to the GreenPower Motor Company Inc. conference call.

Replay: (US) 1-877-344-7529; (Canada) 1-855-669-9658; (International) 1-412-317-0088
Replay access code: 10139743

Webcast link: https://services.choruscall.com/links/gpvrf200227.html

For further information contact:

Fraser Atkinson
Chairman and CEO
(604) 220-8048

Michael Sieffert
CFO
(604) 563-4144

GreenPower Investor Relations
Mike Cole
(949) 444-1341

About GreenPower Motor Company Inc.

GreenPower designs, builds and distributes a full suite of high-floor and low-floor vehicles, including transit buses, school buses, shuttles, a cargo van and a double decker. GreenPower employs a clean-sheet design to manufacture all-electric buses that are purpose built to be battery powered with zero emissions. GreenPower integrates global suppliers for key components, such as Siemens or TM4 for the drive motors, Knorr for the brakes, ZF for the axles and Parker for the dash and control systems. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. For further information go to www.greenpowerbus.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. © 2020 GreenPower Motor Company Inc. All rights reserved.

SOURCE: GreenPower Motor Company Inc

ReleaseID: 577503

ZCentral customers can leverage Leostream to provide advanced policy-based connection management to Z by HP racked workstations and to build flexible hybrid environments.

BOSTON, MA / ACCESSWIRE / February 24, 2020 / Today, Leostream Corporation announced their intention to provide out-of-the-gate support for the newly announced HP ZCentral remote workstation solution, including ZCentral Remote Boost (formerly known as Remote Graphics Software). ZCentral customers can leverage Leostream to provide advanced policy-based connection management to Z by HP racked workstations and to build flexible hybrid environments.

The Leostream platform supports seamless integration for existing HP Remote Graphics Software (RGS) deployments, in addition to a wide range of high-performance display protocols.

For HP's new ZCentral solution, Leostream will provide connection management and brokering support for ZCentral customers who require:

Support for environments requiring additional display protocols beyond ZCentral Remote Boost.
Support for mixed or hybrid infrastructure, with both on-premises and cloud workstations or virtual machines.
Advanced user-policy permissions and secure access controls, including multi-factor authentication and location-aware end-user experience features, such as network printer redirection.

"We are thrilled to expand our close partnership with HP to include support for the new ZCentral solution," remarked Leostream CEO Karen Gondoly. "We believe that the ZCentral solution is ideal for enterprise customers looking for a highly performant remote racked workstation solution. The Leostream Connection Broker will provide out-of-the-gate support for ZCentral in hybrid and otherwise heterogeneous environments, including those with mixed display protocols and secure user access requirements."

"Leostream and the Z by HP team have worked closely to ensure joint customers receive a world-class, remote workstation solution," says Clifton Robin, global software manager, ZCentral. "Out-of-the-gate support for ZCentral is a testament to how committed we are to provide our customers all the functionality needed for an end-to-end remote racked workstation solution."

The Leostream Connection Broker will support ZCentral as soon as the platform is made generally available in Spring 2020. Today, Leostream invites all HP customers considering adopting ZCentral to contact Leostream to conduct a free 30-day proof-of-concept trial with the Leostream Connection Broker. For a limited time, Leostream is offering new HP customers two hours of free setup service for professional assistance configuring the Leostream with ZCentral.

For more information about ZCentral and ZCentral Remote Boost visit hp.com/ZCentral.

For more information about Leostream visit https://leostream.com.

Media Contact:
Robert Ewanouski
Phone: 781-890-2019
Email: sales@leostream.com

SOURCE: Leostream Corporation

ReleaseID: 577498

Prominent players in detox products market are emphasizing maximizing sales with product innovations to bolster efficacy.

DUBAI, UAE / ACCESSWIRE / February 24, 2020 / The detox products industry is projected to rise at a moderate CAGR of 4% between 2019 and 2029. Significant demand for detox products from health-conscious consumers is the predominant factor driving sales. Growing availability of detox and cleansing diet options will continue to aid the growth of the detox products market, reveals Fact.MR in its new study.

"Shifting consumer preference for a healthy lifestyle, complemented by favorable government initiatives, is providing more opportunities for health supplement firms to market immunity-boosting detox products," concludes the Fact.MR report.

Request PDF Sample of the 170-page report on the detox product market-

https://www.factmr.com/connectus/sample?flag=S&rep_id=4496

Detox Products Market – Key Takeaways

Nicotine detoxification products will be a highly lucrative segment through the forecast period.
Pharmacies and drug stores will generate high revenue owing to the application of pharma drugs in end products.
North America will remain the leading regional detox products market, while Asia Pacific will display faster growth.
Manufacturers are pushing for strategic collaborations, mergers, and acquisitions to widen their consumer base.

Detox Products Market – Key Driving Factors

The rapid proliferation of treatment centers worldwide, with a focus on detox remedies, is the primary growth driver.
Favorable government policies towards drug and alcohol rehab centers are contributing towards market growth.
Steady rise in the adoption of detox and cleansing diets significantly support the consumption of detox products.
Consumers are displaying a heightened preference for premium products, enabling the growth of emerging competitors.

Detox Products Market – Key Constraints

High costs associated with pharma detox products are the key restraint to wider consumption.
A number of detox products require the presence of trained practitioners, thereby minimizing adoption.

Explore 104 tables and 217 figures in the study. Request ToC of the report at-

https://www.factmr.com/report/4496/detox-products-market

Competition Landscape

The global detox product market is moderately fragmented. The leading players profiled in the report include, but are not limited to Pfizer Inc., Novartis AG, West-Ward Pharmaceuticals Corp (Hikma), and Detoxify LLC. Market leaders are investing in new product launches. Key players are channeling their efforts in adopting novel, natural ingredients such as herbs, fibers, and greens while offering a broad range of detox product variants. Strategic online and print advertisements are also gaining importance as indicated by the Fact.MR report.

About the Report

This 170-page study offers readers a comprehensive market forecast of the detox product market. Global, regional and country level analysis of the latest industry trends impacting the detox product market are covered in this Fact.MR study. The report offers compelling insights on detox product market on the basis of product type (activated charcoal, cold pressed juice, detox tea, diuretics, superfood mixes, and others), form (liquids, tablets & pallets, powder, capsules, and others), processes (alcohol detoxification, drug detoxification, nicotine detoxification, and metabolic detoxification), buyer type (individual and institutional), and sales channel (drug stores & pharmacies, health & beauty stores, modern trade channels, direct selling, third party online channel, company online channels, and practitioner channels) across seven regions (Middle East and Africa, South Asia, Oceania, East Asia, Europe, Latin America, North America).

Explore Fact.MR's Comprehensive Coverage on Retail & Consumer Goods Landscape

Twist-off Metal Caps Market– Learn more about the major influencing factors affecting the global twist-off metal caps market which is set for strong growth during the projection period (2018-2028).

Smart Clothing Market– Acquire in-depth insights about the global smart clothing market through Fact.MR's detailed report covering end use segments, market dynamics, recent material developments and prominent market players for the forecast period of 2017-2022.

Premium Cosmetics Market– Obtain Fact.MR's exhaustive analysis on the global premium cosmetics market spanning dynamic market factors, key trends and successful strategies of market leaders projected for 2019-2029.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the veteran research team at Fact.MR helps clients from across the globe with their unique business intelligence requirements. With a repository of over thousand reports and 1 million+ data points, the team has scrutinized the Retail & Consumer Goods sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai, United Arab Emirates
MARKET ACCESS DMCC Initiative
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog – https://blog.factmr.com/
PR- https://www.factmr.com/media-release/1277/global-detox-products-market

SOURCE: FactMR

ReleaseID: 577549

INCLINE VILLAGE / ACCESSWIRE / February 24, 2020 / American Battery Metals Corporation (OTCQB:ABML) (the "Company"), an American-owned advanced technology battery recycling and resource production company based in Nevada, today announced that its Chief Executive Officer Doug Cole was recently interviewed by Proactive Investors, a UK-based online investor services company that provides analytics, market reports, and company and industry profiles. The interview focused on it securing a $10 million capital investment commitment from Newood Finance Solutions Limited, a Fiji corporation doing business as Unifinance Limited, an affiliate of VCM Group Pty Limited.

To see the video interview in its entirety, please visit:
https://www.proactiveinvestors.com/companies/news/913459/american-battery-metals-corporation-secures-10m-capital-investment-promise-913459.html.

Doug Cole tells Proactive it has received a promise for a $10 million capital investment from Newood Finance Solutions Limited, a Fiji corporation doing business as Unifinance Limited, an affiliate of VCM Group Pty Limited. Cole says this is the "best partnership we could have" and expects the financing to close in tranches over the next 60 days. The equity financing will be used towards building out the Nevada company's battery recycling plant and to eliminate a portion of its convertible debt.

American Battery Metals Corporation

American Battery Metals Corporation (www.batterymetals.com) (OTCQB:ABML) is an American-owned, advanced technology battery recycling and resource production company based in Nevada. The company is focused on its lithium-ion battery recycling and resource production projects in Nevada, with the goal of becoming a substantial domestic supplier of battery metals to the rapidly growing electric vehicle and battery storage markets in America.

For more information, please visit:www.batterymetals.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including those with respect to the expected project economics for Western Nevada Basin (Railroad Valley), including estimates of life of mine, average production, cash costs, AISC, initial CAPEX, sustaining CAPEX, pre-tax IRR, pre-tax NPV, net cash flows and recovery rates, the impact of self-mining versus contract mining, the timing to obtain necessary permits, the submission of the project for final investment approval and the timing of initial gold production after investment approval and full financing, metallurgy and processing expectations, the mineral resource estimate, expectations regarding the ability to expand the mineral resource through future drilling, ongoing work to be conducted at the Western Nevada Basin (Railroad Valley), and the potential results of such efforts, the potential commissioning of a Pre-Feasibility study and the effects on timing of the project, are "forward-looking statements." Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, interpretations or reinterpretations of geologic information, unfavorable exploration results, inability to obtain permits required for future exploration, development or production, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; fluctuating mineral and commodity prices, final investment approval and the ability to obtain necessary financing on acceptable terms or at all. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended September 30, 2018. The Company assumes no obligation to update any of the information contained or referenced in this press release.

Contact Information

p775-473-4744
info@batterymetals.com

SOURCE: American Battery Metals Corp.

ReleaseID: 577499

Further Extends Company's Biologic Market Opportunities

JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the 15th European Conference on Fungal Genetics ("ECFG15") demonstrated that its C1 strain has been glyco-engineered to achieve a core human like G2 glycan level over 76% on Host Cell Proteins (HCP).

The G2 glycosylation data was presented by Anne Huuskonen from the VTT Technical Research Centre of Finland Ltd ("VTT") at the ECFG15 conference in Rome, Italy on Wednesday, February 19. The scientific results are outlined in the presentation entitled, ''Development of filamentous fungus Myceliophthora thermophila C1 into a next-generation therapeutic protein production system." An overview of the presentation is available on Dyadic's website at:
https://www.dyadic.com/wp-content/uploads/2020/02/VTT-AHuuskonen-Rome-2-19-2020.pdf

"Our collaboration with Dyadic continues to achieve new scientific milestones regarding glycoengineering Dyadic's C1 industrially proven cell line, building upon the 95% core human G0 glycosylation milestone that was reported by Markku Saloheimo, Ph.D., Senior Principal Scientist at VTT, during the PEGS Europe (Protein & Antibody Engineering Summit) in November 2019," said Anne Huuskonen, VTT Senior Scientist.

"Our C1 glycoengineering efforts continue to target our goals in developing C1 cell lines that produce high proportions of human-like glycoforms such as G0, G2, G0F and G2F on heterologous proteins," said Ronen Tchelet, Ph.D., Dyadic's Chief Scientific Officer. "In addition to the glycosylation results, VTT also presented data showing that we continue to make excellent progress in reducing the extracellular protease background by fifty (50) times in C1. The elimination of protease activity makes the C1 cell line more efficient, leading to even higher expression levels and lower cost than before."

"We are very pleased to announce this additional milestone," Matthew Jones, Dyadic's Chief Commercial Officer stated, "These important G0 and G2 glycosylation and other scientific advances further demonstrate the power of our C1 gene expression platform coupled with the dedication and world-class expertise of the VTT scientists. We expect that these scientific achievements will open new doors to apply C1 to a broader array of glycosylated biopharmaceuticals, further extend the Company's market opportunities for biologic vaccines and drugs and continue to generate interest from biotech and pharmaceutical companies, academic and other institutes as well as governmental agencies in animal and human health industries."

About VTT Technical Research Centre of Finland Ltd

VTT Technical Research Centre of Finland Ltd is one of the leading research and technology organizations in Europe. VTT has a national mandate in Finland. We use our research and knowledge to provide expert services for our domestic and international customers and partners. We serve both private and public sectors. We have 75 years' experience supporting our clients growth with top-level research and science-based results. For more information, please visit http://www.vttresearch.com/.

About Dyadic International

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Recently, Dyadic has also begun exploring the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to create synergy by leveraging Dyadic's technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and as a result improve access and cost to patients and the healthcare system, and most importantly, save lives.

Please visit Dyadic's website at www.dyadic.com for additional information, including details regarding Dyadic's plans for its biopharmaceutical business.

Safe Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic's expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in Dyadic's most recent filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled "Risk Factors" in Dyadic's annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic's periodic filings with the SEC, which are accessible on the SEC's website at www.dyadic.com.

Contact:

Dyadic International, Inc.
Mark A. Emalfarb
Chief Executive Officer
Phone: (561) 743-8333
Email: mailto:memalfarb@dyadic.com

SOURCE: Dyadic International, Inc.

ReleaseID: 577373

SANTA FE, NM / ACCESSWIRE / February 24, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) ("Sigma Labs"), a leading developer of quality assurance software for the commercial 3D printing industry, today announced that management will present at the LD Micro Virtual Investor Conference on March 4, 2020 at 1:00 p.m. Eastern time.

Mark K. Ruport, Executive Chairman of Sigma Labs, will present an overview of the business model and growth initiatives. The webinar will be accompanied by a presentation and followed by a question and answer session, which can be accessed via the webcast link below.

To access the webinar, please use the following information:

LD Micro Virtual
Date: Wednesday, March 4, 2020
Time: 1:00 p.m. Eastern time (10:00 a.m. Pacific time)
Webcast: https://www.webcaster4.com/Webcast/Page/2019/33290

About Sigma Labs

Sigma Labs, Inc. (NASDAQ:SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs' advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, please visit www.sigmalabsinc.com.

Contacts:

Media Contact:

Julia Wakefield
Vice President
Rubenstein Public Relations
212-805-3021
jwakefield@rubensteinpr.com
www.rubensteinpr.com

Investor Contact:

Chris Tyson
Managing Director
MZ Group – MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us

SOURCE: Sigma Labs, Inc.

ReleaseID: 577178

TORONTO, ONTARIO / ACCESSWIRE / February 24, 2020 / Matica Enterprises Inc. (CSE:MMJ) (Frankfurt: 39N) (OTCQB:MMJFF) ("Matica" or the "Company") is pleased to announce that its subsidiary, RoyalMax Biotechnology Canada  Inc. ("RoyalMax"), has received both the Standard Processing and Sale For Medical Purposes Licences from Health Canada. The standard processing licence will allow RoyalMax to deliver products to the recreational market throughout Canada. With the medical sales licence RoyalMax, will be able to provide product directly to appropriately documented patients who use cannabis for medical purposes.

RoyalMax will immediately initiate its marketing and distribution program to bring high quality Quebec grown cannabis to store shelves. Royal Max currently has over 400 kilograms of internally produced product. Further, RoyalMax will be working with partner growers that want to take advantage of RoyalMax's distribution channels to deliver cannabis and related products to consumers.

Matica CEO Boris Ziger states, "We have hit yet another major milestone in the development of our Company. As this is a big moment for us, I want thank all of our supporters and stakeholders who have stuck with us through this long process. We are a Quebec based company, it is important to demonstrate that Quebec can produce high quality product and to bring it to the rest of Canada."

About Matica

Matica is a multi-faceted, innovative company in the Quebec cannabis space. Its subsidiary, RoyalMax Biotechnology Canada Inc. is a Dorval, Quebec based Health Canada Licence Holder. RoyalMax has been granted a standard cultivation licence, standard processing and medical sales licences by Health Canada. In the township of Hemmingford, Matica is building 1,000,000 square feet of greenhouse growing space, in 200,000 square foot increments, on a sprawling 181 acre property.

For more information on Matica Enterprises please visit the website at: www.maticaenterprises.com.

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

Boris Ziger
Boris Ziger, CEO & Chairman

The Company's public filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, at:

Telephone: 416-304-9935
E-mail: info@maticaenterprises.com
Website: www.maticaenterprises.com , www.maticammj.com

Disclaimer for Forward-Looking Information

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.

This news release contains statements about the Company's information that may be made available on the S&P Capital IQ Corporation Records Listing Program and the business of Matica that are forward-looking in nature and as a result, are subject to certain risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from the forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. We seek Safe Harbor.

SOURCE: Matica Enterprises Inc.

ReleaseID: 577510

DENVER, CO / ACCESSWIRE / Februay 24, 2020 / AmeriCann, Inc. (OTCQB:ACAN) a cannabis company that is developing state-of-the-art cultivation, processing and product manufacturing facilities, announced record financial results for its first quarter ended December 31, 2019.

First Quarter December 31, 2019 Financial & Operational Highlights:

Record net income of $1,017,985
EBITDA of $1,325,850.
Completion of Building 1 at the Massachusetts Cannabis Center, the Company's flagship cannabis development which will include up to one million square feet of sustainable greenhouse cultivation, processing and product manufacturing infrastructure.

CEO Tim Keogh stated, "Our first quarter financial results reflect, in part, the operating efficiencies AmeriCann has achieved. Additionally, we look forward to the impact that the commencement of operations at Building 1 will provide the Company going forward, which we expect to launch in our current quarter."

About AmeriCann

AmeriCann (OTCQB:ACAN) is a cannabis company that is developing cultivation, processing and product manufacturing facilities.

AmeriCann uses greenhouse technology which is superior to the current industry standard of growing cannabis in warehouse facilities under artificial lights. According to industry experts, by capturing natural sunlight, greenhouses use 25 percent fewer lights, and utility bills are up to 75 percent less than in typical warehouse cultivation facilities. As such, AmeriCann's Cannopy System enables cannabis to be produced with a greatly reduced carbon footprint, making the final product less expensive. Additionally, greenhouse construction costs are nearly half of warehouse construction costs.

AmeriCann is also designing GMP Certified cannabis extraction and product manufacturing infrastructure. Through a wholly-owned subsidiary, AmeriCann Brands, Inc., the Company intends to secure licenses to produce cannabis infused products including beverages, edibles, topicals and concentrates. AmeriCann Brands, Inc. plans to operate a Marijuana Product Manufacturing business at the Massachusetts Cannabis Center with over 40,000 square feet of state-of-the art extraction and product manufacturing infrastructure.

More information about the Company is available at: www.americann.co, or follow AmeriCann at @ACANinfo on Twitter, @AmeriCann on Facebook, @AmeriCannInc on Instagram, AmeriCann, Inc on LinkedIn

About Massachusetts Cannabis Center

The Massachusetts Cannabis Center (MCC), is a one million square foot sustainable greenhouse facility in Freetown, Mass which is being developed by AmeriCann. The first phase of the facility is scheduled to commence operations for cannabis cultivation, processing, and infused product production by the end of 2019. Once fully developed, the MCC design calls for a research facility, a training center, corporate offices, a quality-assurance laboratory, and a facility for manufacturing cannabis-infused food, nutraceuticals and consumer packaged cannabis goods.

AmeriCann plans to replicate the brands, technology and innovations developed at its MCC project in new markets as a licensed multi-state operator (MSO).

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional uncertainties that could impact the Company's forward-looking statements, please see the Company's Registration Statement on Form S-1, which the Company recently filed with the SEC and which may be viewed at www.sec.gov.

About Non-GAAP Financial Measures

The Company uses "adjusted EBITDA," as a non-GAAP financial measure to evaluate financial performance such as period-to-period comparisons. This non-GAAP measure is not defined under U.S. GAAP and should be considered in addition to, not as a substitute for, indicators of financial performance reported in accordance with U.S. GAAP. The Company may use non-GAAP measures that are not comparable to measures with similar titles reported by other companies. Also, in the future, the Company may disclose different non-GAAP financial measures in order to help investors more meaningfully evaluate and compare the Company's future results of operations to its previously reported results. The Company encourages investors to review its financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. The section titled "Reconciliation of Non-GAAP Financial Measures" includes a detailed description of this measure as well as a reconciliation to its most similar U.S. GAAP measure.

Reconciliation of Non-GAAP Financial Measures

The Company defines adjusted EBITDA as net income adjusted to exclude the impact of interest expense, interest income, income taxes, depreciation, depletion and amortization, stock based compensation, impairment, and the plus or minus change in fair value of derivative assets or liabilities. The Company believes adjusted EBITDA is relevant because it is a measure of cash flow available to fund capital expenditures and service debt and is a metric used by some industry analysts to provide a comparison of its results with its peers. The following table presents a reconciliation of the Company's non-GAAP financial measures to the nearest GAAP measure.

Contact Information:

Corporate:
AmeriCann, Inc.
1550 Wewatta Street
2nd Floor
Denver, CO 80202
(303) 862-9000
info@americann.co
www.americann.co
@ACANinfo on Twitter
@AmeriCann on Facebook
@AmeriCannInc on Instagram
AmeriCann, Inc on LinkedIn

SOURCE: AmeriCann, Inc.

ReleaseID: 577547